Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-09-02FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (Epic Pharma LLC)
FDA approved a supplemental application for bupropion hydrochloride from Epic Pharma LLC, indicating approval of a generic formulation.
-
FDA approval · 2022-08-31FDA Approved: CITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for citalopram hydrobromide by Aurobindo Pharma Limited, representing a generic version of citalopra…
-
FDA approval · 2022-08-30FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride as a generic, confirming approval under the ANDA p…
-
FDA label_change · 2022-08-30FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for a sertraline hydrochloride generic from Quallent Pharmaceuticals Health LLC, updating the labeli…
-
FDA approval · 2022-08-30FDA Approved: VENLAFAXINE — Original Application (Zydus Lifesciences Limited)
FDA approved the original application (ANDA) for venlafaxine from Zydus Lifesciences Limited, enabling generic access to the antidepressant.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-25Clinical Trial Update: Treatment of Depression With Connectivity Guided Robotically Delivered rTMS [NA]
Clinical trial update for a study on connectivity-guided robotically delivered rTMS in major depressive disorder; study status terminated wi…
-
FDA approval · 2022-08-24FDA Approved: QUETIAPINE — Original Application (Solco Healthcare US, LLC)
FDA approves Solco Healthcare's original application for a generic quetiapine product (quetiapine fumarate tablets), enabling a generic vers…
-
CLINICAL_TRIALS research · 2022-08-23Clinical Trial Update: DDBT Adapted Problem Solving Treatment for Primary Care [NA]
Clinical trial update on adapted problem solving treatment for primary care showing completed status with results posted.
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: An EEG Study of Intravenous Ketamine for Major Depression Disorder [Phase 4]
Clinical trial update for intravenous ketamine in major depressive disorder (Phase 4) with unknown status.
-
CLINICAL_TRIALS trial_result · 2022-08-19Clinical Trial Update: A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder [Phase 2]
Phase 2 clinical trial update for PRAX-114 as adjunctive and monotherapy in major depressive disorder has completed.
-
FDA approval · 2022-08-18FDA Approved: AUVELITY — Original Application (Axsome Therapeutics, Inc.)
AUVELITY is FDA-approved as a fixed-dose combination of dextromethorphan hydrobromide and bupropion hydrochloride for the treatment of adult…
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy [Phase 2]
Phase 2 trial comparing JNJ-42847922 to quetiapine extended-release as adjunctive therapy to antidepressants in adults with major depressive…
-
FDA approval · 2022-08-15FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) from Viatris Specialty LLC.
-
FDA approval · 2022-08-15FDA Approved: QUETIAPINE — Original Application (BluePoint Laboratories)
FDA approved a generic version of quetiapine from BluePoint Laboratories under an Original Application (ANDA 215478).
-
FDA approval · 2022-08-09FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Venlafaxine Hydrochloride (extended-release) submitted by Chartwell RX, LLC.
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: Vortioxetine in Patients With Depression and Early Dementia [Phase 4]
Phase 4 clinical trial update of vortioxetine in patients with major depressive disorder and dementia completed.
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: BRITEPath, Component 3 of iCHART (Integrated Care to Help At-Risk Teens) [NA]
A completed trial update for BRITEPath, part of iCHART, studying depression and suicidal ideation in at-risk teens; results posted in 2022.
-
CLINICAL_TRIALS withdrawal · 2022-08-05Clinical Trial Update: ECT vs. Esketamine [Phase 3]
A Phase 3 clinical trial comparing electroconvulsive therapy (ECT) versus esketamine for treatment resistant depression and major depressive…
-
CLINICAL_TRIALS trial_result · 2022-08-02Clinical Trial Update: Zelquistinel in the Treatment of Major Depressive Disorder [Phase 2]
A Phase 2 trial evaluating Zelquistinel for major depressive disorder has completed and results have been posted.
-
FDA approval · 2022-07-29FDA Approved: DULOXETINE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
FDA approved a supplemental application for duloxetine filed by Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: Prophylactic Effects of Agomelatine for Poststroke Depression [Phase 4]
Phase 4 trial update investigating prophylactic effects of agomelatine for post-stroke depression.
-
FDA approval · 2022-07-26FDA Approved: DULOXETINE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for DULOXETINE submitted by Quallent Pharmaceuticals Health LLC. The notice confirms regulatory …
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder [Phase 2, Phase 3]
Clinical trial update for PRAX-114 in participants with Major Depressive Disorder (Phase 2/Phase 3) completed.
-
CLINICAL_TRIALS trial_result · 2022-07-18Clinical Trial Update: Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study [NA]
A completed pilot study evaluating development, feasibility, and acceptability of the Fathers and Babies (FAB) program for perinatal and pos…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Mechanistic Evaluation of Response in TRD (MERIT) [Phase 2]
Phase 2 clinical trial evaluating mechanistic response in treatment resistant depression and major depressive disorder has completed.